(Q38400396)

2 September 2017

1 reference

title

Chimeric fusion proteins used for therapy: indications, mechanisms, and safety (English)

1 reference

2 September 2017

Brian A Baldo

1

1 reference

2 September 2017

1 May 2015

1 reference

2 September 2017

1 reference

2 September 2017

38

1 reference

2 September 2017

5

1 reference

2 September 2017

455-479

1 reference

https://scigraph.springernature.com/pub.10.1007/s40264-015-0285-9

2 September 2017

0 references

cites work

Protein therapeutics: a summary and pharmacological classification

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Side effects of cytokines approved for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Fc-fusion proteins: new developments and future perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Versatile characterization of glycosylation modification in CTLA4-Ig fusion proteins by liquid chromatography-mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

FcRn: the neonatal Fc receptor comes of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Immune and non-immune functions of the (not so) neonatal Fc receptor, FcRn.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Dependence of antibody-mediated presentation of antigen on FcRn

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Antibody therapeutics: isotype and glycoform selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Metabolic properties of IgG subclasses in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Prolonged and effective blockade of tumor necrosis factor activity through adenovirus-mediated gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Granulomatous infectious diseases associated with tumor necrosis factor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Exercise capacity and mortality among men referred for exercise testing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Experience with etanercept in an academic medical center: are infection rates increased?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Tuberculous tonsillitis in a patient receiving etanercept treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Fatal group A Streptococcus purpura fulminans in a child receiving TNF-α blocker

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Does etanercept monotherapy enhance the risk of Listeria monocytogenes meningitis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Severe pneumonia by aciclovir-resistant varicella-zoster virus during etanercept therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Etanercept: a review of its use in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Accelerated nodulosis and vasculitis following etanercept therapy for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Appearance of ANCA - associated vasculitis under Tumor necrosis factor-alpha inhibitors treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Etanercept: an overview of dermatologic adverse events.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Urticaria due to etanercept in a patient with psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Psoriasis after treatment of juvenile idiopathic arthritis with etanercept

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Etanercept-induced lichenoid reaction pattern in psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Severe skin reaction after leflunomide and etanercept in a patient with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Development of pemphigus vulgaris in a patient with psoriasis treated with etanercept

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Acute generalized exanthematous pustulosis induced by etanercept: another dermatologic adverse effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Multiple sclerosis onset during etanercept treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Anti-tumor necrosis factor alpha therapy and the risk of lymphoma in rheumatoid arthritis: no clear answer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Tumor necrosis factor antagonists in the therapy of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Re-challenge with etanercept in patients with etanercept-induced neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Lymphopenia induced by etanercept.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Lung injury linked to etanercept therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Pulmonary granulomas after tumour necrosis factor alpha antagonist therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Exacerbation of interstitial lung disease during etanercept therapy: Two cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Organizing pneumonia in a patient with rheumatoid arthritis treated with etanercept

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Biologics-induced autoimmune renal disorders in chronic inflammatory rheumatic diseases: systematic literature review and analysis of a monocentric cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Cutaneous lupus induced by etanercept in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Anaphylaxis to etanercept in two children with juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Angio-oedema in a patient treated with etanercept for rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Eosinophilic cellulitislike reaction to subcutaneous etanercept injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

A two-step, two-signal model for the primary activation of precursor helper T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Summary of the US FDA approval of belatacept

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Belatacept: a novel biologic for maintenance immunosuppression after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Abatacept in psoriatic arthritis: Case report and short review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Subcutaneous abatacept for the treatment of rheumatoid arthritis: longterm data from the ACQUIRE trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Abatacept in B7-1-positive proteinuric kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Cytokine traps: multi-component, high-affinity blockers of cytokine action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Long-term efficacy and safety profile of rilonacept in the treatment of cryopryin-associated periodic syndromes: results of a 72-week open-label extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

VEGF-Trap: a VEGF blocker with potent antitumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein Occlusion: One-Year Results of the Phase 3 GALILEO Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Peptibodies: A flexible alternative format to antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Romiplostim or standard of care in patients with immune thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Repeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Interleukin 2 receptor-targeted cytotoxicity. Interleukin 2 receptor-mediated action of a diphtheria toxin-related interleukin 2 fusion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Internalization of interleukin 2 is mediated by the beta chain of the high-affinity interleukin 2 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Toxic epidermal necrolysis associated with denileukin diftitox (DAB389IL-2) administration in a patient with follicular large cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Fc fusion as a platform technology: potential for modulating immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Hypersensitivity reactions to biologic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0285-9

Injection-site reaction to etanercept: role of skin test in the diagnosis of such reaction and successful desensitization

21 January 2018

1 reference

12 December 2020

Pulmonary aspergillosis in a patient with rheumatoid arthritis treated by etanercept

1 reference

12 December 2020

Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma

1 reference

12 December 2020

Human antibody effector function

1 reference

12 December 2020

Safety and tolerability of infliximab therapy: suggestions and criticisms based on wide clinical experience

1 reference

12 December 2020

Successful etanercept desensitization in a patient with severe injection site reactions

1 reference

12 December 2020

Septic arthritis caused by Actinobacillus ureae in a patient with rheumatoid arthritis receiving anti-tumor necrosis factor-alpha therapy

1 reference

12 December 2020

Transient hyperthyroidism in a patient with rheumatoid arthritis treated by etanercept

1 reference

12 December 2020

Aflibercept in the treatment of metastatic colorectal cancer

1 reference

12 December 2020

A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis

1 reference

12 December 2020

Cerebral toxoplasmosis following etanercept treatment for idiophatic pneumonia syndrome after autologous peripheral blood progenitor cell transplantation (PBPCT)

1 reference

12 December 2020

Psoriasiform lesions appearing in three patients with rheumatoid arthritis during therapeutic administration of abatacept, a selective inhibitor of T-cell costimulation

1 reference

12 December 2020

Management of accelerated pulmonary nodulosis following etanercept therapy in a patient with rheumatoid arthritis

1 reference

12 December 2020

Cutaneous vasculitis and glomerulonephritis in a patient taking the anti-TNF alpha agent etanercept for rheumatoid arthritis

1 reference

12 December 2020

A case of rheumatoid arthritis complicated by demyelination in both cerebral cortex and spinal cord during etanercept therapy

1 reference

12 December 2020

Immunologic responses to therapeutic biologic agents.

1 reference

12 December 2020

Neutropenia in patients receiving anti-tumor necrosis factor therapy

1 reference

12 December 2020

Mechanistic aspects of inflammation and clinical management of inflammation in acute gouty arthritis

1 reference

12 December 2020

Severe generalized exanthema due to etanercept given for severe plaque psoriasis

1 reference

12 December 2020

Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents.

1 reference

12 December 2020

Etanercept and urticaria in patients with juvenile idiopathic arthritis.

1 reference

12 December 2020

Psoriasiform drug eruption due to abatacept

1 reference

12 December 2020

Psoriasiform reactions during treatment with abatacept

1 reference

12 December 2020

Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept

1 reference

12 December 2020

Recurrent varicella in an adult psoriasis patient treated with etanercept

1 reference

12 December 2020

Neurological disorders with demyelinating brain white matter lesions in a patient with rheumatoid arthritis treated with etanercept

1 reference

12 December 2020

Hypersensitivity reactions during treatment with infliximab, etanercept, and adalimumab

1 reference

12 December 2020

Effectiveness and safety of etanercept in patients with psoriatic arthritis in a Canadian clinical practice setting: the REPArE trial

1 reference

12 December 2020

Viral pneumonia as a serious complication of etanercept therapy

1 reference

12 December 2020

Etanercept allergy and anaphylaxis

1 reference

12 December 2020

Is there a link between the use of etanercept and Henoch-Schönlein purpura? Comment on: Henoch-Schonlein purpura in a patient with the rheumatoid arthritis receiving etanercept (Eur J Dermatol 2010; 20: 521-2).

1 reference

12 December 2020

Structure/function analysis of interleukin-2-toxin (DAB486-IL-2). Fragment B sequences required for the delivery of fragment A to the cytosol of target cells

1 reference

12 December 2020

Etanercept-induced subacute cutaneous lupus erythematosus

1 reference

12 December 2020

Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001)

1 reference

12 December 2020

Acute exacerbation of preexisting interstitial lung disease after administration of etanercept for rheumatoid arthritis.

1 reference

12 December 2020

Immune-mediated agranulocytosis related to drugs and their metabolites: mode of sensitization and heterogeneity of antibodies

1 reference

12 December 2020

Benefits and risks of biological agents: lymphomas.

1 reference

12 December 2020

Multifocal septic arthritis and osteomyelitis caused by group A Streptococcus in a patient receiving immunomodulating therapy with etanercept

1 reference

12 December 2020

Three significant cases of neutropenia with etanercept

1 reference

12 December 2020

Ophthalmic manifestations of demyelination secondary to etanercept

1 reference

12 December 2020

Treatment of refractory tumor necrosis factor inhibitor-induced palmoplantar pustulosis: a report of 2 cases

1 reference

12 December 2020

Psoriatic lesions induced by antitumour necrosis factor-alpha treatment: two cases

1 reference

12 December 2020

A multicenter dose-escalation trial with denileukin diftitox (ONTAK, DAB(389)IL-2) in patients with severe psoriasis

1 reference

12 December 2020

Leukocytoclastic vasculitis due to etanercept

1 reference

12 December 2020

TNF-antagonist etanercept induced reversible posterior leukoencephalopathy syndrome

1 reference

12 December 2020

Pulmonary rheumatoid nodules in an etanercept-treated patient

1 reference

12 December 2020

Worsening of macrophage activation syndrome in a patient with adult onset Still's disease after initiation of etanercept therapy

1 reference

12 December 2020

Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients

1 reference

12 December 2020

Echinococcus multilocularis infection and TNF inhibitor treatment in a patient with rheumatoid arthritis

1 reference

12 December 2020

Etanercept Treatment for Children and Adolescents with Plaque Psoriasis

1 reference

12 December 2020

Demyelinating disease and cutaneous lymphocitic vasculitis after etanercept therapy in a patient with rheumatoid arthritis

1 reference

12 December 2020

Rilonacept (arcalyst), an interleukin-1 trap for the treatment of cryopyrin-associated periodic syndromes.

1 reference

12 December 2020

Atopic dermatitis as a side effect of anti-tumor necrosis factor-alpha therapy

1 reference

12 December 2020

A mechanism-based classification of dermatologic reactions to biologic agents used in the treatment of cutaneous disease: Part 2.

1 reference

12 December 2020

Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors

1 reference

12 December 2020

TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group

1 reference

12 December 2020

Delayed multiple injection site reaction in a rheumatoid arthritis patient treated with etanercept

1 reference

12 December 2020

Paraplegia in a patient receiving anti-tumor necrosis factor therapy for rheumatoid arthritis: comment on the article by Mohan et al

1 reference

12 December 2020

Etanercept urticaria in a patient with psoriasis desensitized using a new method

1 reference

12 December 2020

Henoch-Schönlein purpura after etanercept therapy for psoriasis

1 reference

12 December 2020

Etanercept: effectiveness and safety data of a retrospective study

1 reference

12 December 2020

The development of erythema elevatum diutinum in a patient with juvenile idiopathic arthritis under treatment with abatacept

1 reference

12 December 2020

Long-term etanercept in pediatric patients with plaque psoriasis

1 reference

12 December 2020

Angiokeratoma induced by injection of etanercept for psoriasis

1 reference

12 December 2020

Aplastic anemia following administration of a tumor necrosis factor-alpha inhibitor

1 reference

12 December 2020

Autoimmune skin rashes associated with etanercept for rheumatoid arthritis

1 reference

12 December 2020

Transformed mycosis fungoides developing after treatment with alefacept

1 reference

12 December 2020

Safety of T-cell co-stimulation modulation with abatacept in patients with rheumatoid arthritis.

1 reference

12 December 2020

Mycobacteria tuberculosis peritonitis associated with etanercept therapy

1 reference

12 December 2020

A case of antisynthetase syndrome in a rheumatoid arthritis patient with anti-PL-12 antibody following treatment with etanercept

1 reference

12 December 2020

Letter: A case of generalized guttate psoriasis induced by etanercept with relapse after abatacept

1 reference

12 December 2020

Acute progression of interstitial lung disease: a complication of etanercept particularly in the presence of rheumatoid lung and methotrexate treatment

1 reference

12 December 2020

Etanercept-induced dermatitis in a patient with rheumatoid arthritis

1 reference

12 December 2020

Injection site reactions to TNF-alpha blocking agents with positive skin tests

1 reference

12 December 2020

Rapid subcutaneous desensitization for the management of local and systemic hypersensitivity reactions to etanercept and adalimumab in 12 patients

1 reference

12 December 2020

Development of rheumatoid nodules during anti-tumor necrosis factor alpha therapy with etanercept

1 reference

12 December 2020

Reversible bone marrow reticulin fibrosis as a side effect of romiplostim therapy for the treatment of chronic refractory immune thrombocytopenia

1 reference

12 December 2020

Biologics in the management of psoriasis.

1 reference

12 December 2020

Etanercept and infliximab associated with cutaneous vasculitis

1 reference

12 December 2020

Rapid onset and fatal outcome of two squamous cell carcinomas of the genitalia in a patient treated with etanercept for cutaneous psoriasis

1 reference

12 December 2020

Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition

1 reference

12 December 2020

Rapid onset of cutaneous squamous cell carcinoma of the penis in a patient with psoriasis on etanercept therapy

1 reference

12 December 2020

Recall injection-site reactions associated with etanercept therapy: report of two new cases with immunohistochemical analysis

1 reference

12 December 2020

Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: Fc fusion protein.

1 reference

12 December 2020

Leukoencephalopathy during administration of etanercept for refractory rheumatoid arthritis

1 reference

12 December 2020

Leukopenia and thrombocytopenia induced by etanercept: two case reports and literature review.

1 reference

12 December 2020

A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study)

1 reference

12 December 2020

10.1007/S40264-015-0285-9

Identifiers

DOI

1 reference

PubMed ID

25832756

Dimensions Publication ID

2 September 2017

0 references

1 reference

PubMed ID

25832756